Prot #109MS412:A multicenter, retrospective, observational study evaluating real-world clinical outcomes in relapsing-remitting multiple sclerosis patients who transition from Tysabri® (natalizumab) to Tecfidera® (dimethyl fumarate)

Project: Research project

Project Details

StatusFinished
Effective start/end date10/29/1410/29/17

Funding

  • Quintiles, Inc. (109MS412)
  • Biogen Inc. (109MS412)